Compare PARK & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | VTVT |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 104.9M |
| IPO Year | 2025 | 2015 |
| Metric | PARK | VTVT |
|---|---|---|
| Price | $21.35 | $21.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $28.50 | ★ $56.00 |
| AVG Volume (30 Days) | ★ 45.2K | 14.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.58 | N/A |
| Revenue Next Year | $15.70 | N/A |
| P/E Ratio | $136.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.39 | $20.56 |
| 52 Week High | $26.79 | $44.00 |
| Indicator | PARK | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 22.64 |
| Support Level | $17.82 | N/A |
| Resistance Level | $26.79 | $34.65 |
| Average True Range (ATR) | 1.46 | 1.40 |
| MACD | 0.18 | -0.34 |
| Stochastic Oscillator | 99.25 | 4.59 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.